LONDON (ShareCast) - (Sharecast News) - Neuroscience data analytics company Ixico has secured new contracts in Alzheimer's disease (AD) clinical trials, it announced on Tuesday.
The AIM-traded firm said the new contracts included a phase 1 study in Alzheimer's disease with a new biotechnology customer, an expansion contract for a phase 2 trial with an existing biotechnology company, and the initiation of an open-label extension phase 3 trial with an existing large pharmaceutical company.

It said the contracts built on the strength it had in AD clinical trials, and were in addition to the partnership with the Global Alzheimer's Platform, which it announced on 21 September.

The contracts were included in the company's expectations of performance for the coming year, and contributed to its "strong" order book, the board said.

It added that they related to trials at different stages of drug development, and were with "several different customers", strengthening diversification in its order book as well.

"Today there are 50 million people worldwide that suffer from Alzheimer's and other forms of dementias," said chief commercial officer Lammert Albers.

"There are currently no means to prevent or delay onset, slow progression or meaningfully improve symptoms of Alzheimer's disease.

"With more than 120 unique investigational drugs in clinical trials, Ixico is proud to support some of these potential treatments that one day may be in the hands of Alzheimer's patients worldwide."

At 0917 GMT, shares in Ixico were up 5.85% at 105.84p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE